The concentration and microheterogeneity of acute-phase proteins in patients with systemic sclerosis

The concentration and microheterogeneity of acute-phase proteins (APP) differ in acute and chronic types of inflammation. The qualitative changes of some acute-phase glycoproteins are referred to as major microheterogeneity. Affinity electrophoresis with a lectin, concanavalin A (ConA), as a ligand has been successfully used to determine acute-phase glycoproteins microheterogeneity. The concentration and microheterogeneity of acute-phase proteins can be used in early diagnosis, management and prognosis of chronic inflammatory stages including Systemic Sclerosis (SS). The study included 45 patients with SS with a mean age of 46.2 years. All patients fulfilled the American Rheumatism Association revised criteria for classification of SS. The control group comprised 15 healthy individuals with a mean age of 42.3 years. Serum levels of acid-glycoprotein (AGP), antichymotrypsin (ACT) and ceruloplasmin (CP) were measured by electroimmunoassay using anti-AGP, anti-ACT and anti-CP antibodies. The level of C-reactive protein (CRP) was determined by radial immunodiffusion with anti-CRP antibodies. The microheterogeneity of the acute-phase proteins was assessed by agarose affinity electrophoresis using Con A as a ligand, as described by Břg-Hansen. The increased concentration of only a few proteins (AGP, CRP, CP) was found. A moderate rise of CRP, CP and AGP levels in about 50% of SS cases was associated with arthritis and cutaneous ulcers. High levels of proteins were observed in a group with pulmonary and heart involvement. Microheterogeneity of acutephase proteins was changed in studied patients and showed different pictures. Our results support the changed acute-phase response in patients with systemic sclerosis. S t r e s z c z e n i e

[1]  M. Tomšič,et al.  Acute Phase Proteins in Prototype Rheumatic Inflammatory Diseases , 2011 .

[2]  M. Matucci-Cerinic,et al.  Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.

[3]  P. Zatloukal,et al.  Clinical Correlations of Potential Activity Markers in Systemic Sclerosis , 2005, Annals of the New York Academy of Sciences.

[4]  C. Chizzolini.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples , 2004, Springer Seminars in Immunopathology.

[5]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[6]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[7]  L. Brzezińska-Wcisło,et al.  Acute-Phase Proteins in Patients with Systemic Sclerosis , 2000, Clinical Rheumatology.

[8]  D. Furst.  The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? , 1999, Journal des maladies vasculaires.

[9]  B. White,et al.  Immunopathogenesis of systemic sclerosis. , 1996, Rheumatic diseases clinics of North America.

[10]  A. Postlethwaite,et al.  Role of T cells and cytokines in effecting fibrosis. , 1995, International reviews of immunology.

[11]  E. Leroy,et al.  Cytokines and systemic sclerosis. , 1994, Clinics in dermatology.

[12]  T. Wilson,et al.  Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens. , 1991, Journal of autoimmunity.

[13]  Maricq Hr,et al.  Microvasculature in systemic sclerosis. , 1990 .

[14]  L. Pagano,et al.  Evaluation of some inflammatory, coagulative and immune parameters in progressive systemic sclerosis. , 1988, Acta medica Polona.

[15]  J. Hansen,et al.  Electrophoretic analysis of the glycan microheterogeneity of orosomucoid in cancer and inflammation , 1986 .

[16]  R M Silver,et al.  Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. , 1984, The American journal of medicine.

[17]  J. Seibold,et al.  Alpha-1-antitrypsin in progressive systemic sclerosis. , 1980, Arthritis and rheumatism.

[18]  C. Laurell,et al.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.